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Abstract Tryptophan is an essential amino acid
involved in the protein synthesis, cognition, and
immunity. Oxidative catabolism of tryptophan is exe-
cuted by the sets of biochemical reactions collectively
referred to as the kynurenine pathway. In the immune
system, two distinct enzymes, Indoleamne 2,3 dioxy-
genase 1 (IDO1) and Indoleamine 2, 3 dioxygenase 2
(IDO2) can initiate metabolic flux through the kynu-
renine pathway. Rheumatoid arthritis is an autoimmune
disease driven by the exacerbated immune response
towards self antigens and characterized by the chronic
inflammatory reaction of the diarthrodial joints. Colla-
gen induced arthritis (CIA) is an animal model of
rheumatoid arthritis. Using CIA in wild type (WT) and
mice deficient with Indoleamine 2,3 dioxygenase
(Ido1KO), it was of interest to test the impact of Ido1
deletion on the concentration of tryptophan and its
catabolites as well as on mRNA expression for other
genes on the kynurenine pathway. Here, when com-
pared with samples taken from naı¨ve WT animals and
those with CIA, it was found that only in the inguinal
lymph nodes (iLN) taken from Ido1KO mice with CIA
tryptophan concentration was significantly increased.
In contrast, mRNA expression for Ido2 was decreased
in naı¨ve as well as in the diseased iLN taken from
Ido1KO mice. Deletion of Ido1 and reduced mRNA
expression for Ido2 neither affected the concentration
of the downstream metabolites of tryptophan nor
mRNA expression for downstream genes on the
kynurenine pathway in iLN. Moreover, the concentra-
tion of kynurenine in sera of mice with CIA was
significantly decreased in Ido1KO mice with arthritis.
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Introduction
Tryptophan is an essential amino acid implicated in the
regulation of various biological processes including
mood (Russo et al. 2003) and immunity (Moffett and
Namboodiri 2003). Indoleamnine 2, 3 dioxygenase 1
(IDO1) is an initial enzyme which catalyses oxidative
degradation of tryptophan via the kynurenine pathway
(Fig. 1) (Hayaishi 1976). Hence, not surprisingly, IDO1
and the kynurenine pathway have been extensively
investigated (Kolodziej et al. 2011). Therefore, mice
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deficient in Ido1 (Ido1KO) are a vital tool in the research
on IDO1 mediated tryptophan degradation (Baban et al.
2004). Moreover, another enzyme, Indoleamine 2, 3
dioxygenase 2 (IDO2), which is also able to catalyze
oxidative catabolism of tryptophan via the kynurenine
pathway, has been recently discovered (Metz et al. 2007).
Interestingly, Ido1 and Ido2 are located on the same
chromosome in the close proximity to each other (Ball
et al. 2007). Hence, it could be predicted deletion of Ido1
could be compensated by the increased expression of
Ido2 mRNA, resulting in the decreased concentration of
tryptophan in Ido1KO mice despite inactivation of IDO1.
In the immune system, tryptophan has been impli-
cated in the immune regulation (Moffett and Namboodiri
2003). The decreased concentration of this amino acids
leads to cell cycle arrest (Frumento et al. 2002; Munn
et al. 1999) and apoptosis (Fallarino et al. 2002). In
addition, toxic byproducts of tryptophan degradation via
the kynrenine pathway are potent inducers of apoptosis
in T cells (Kolodziej et al. 2011; Terness et al. 2002).
IDO1 mediated tryptophan catabolism has been also
proven to be important in the biology of Th17 and Treg
cells (Baban et al. 2009; Sharma et al. 2009). Th17 cells
exacerbate inflammation (Weaver et al. 2006), whereas
Treg cells exhibit potent anti-inflammatory activity
(Zaiss et al. 2007). Interestingly, tryptophan starvation
accompanied with accumulation of its toxic byproducts
e.g. anthranilic acid (AA) and 3-hydroxyanthranilic acid
(3-HAA) has been shown to abrogate function of Th17
cells in a dose dependent manner (Desvignes and Ernst
2009). In addition, the same conditions have been proven
to promote the development of Treg’s (Fallarino et al.
2006). Thus, in the context of metabolic regulation,
Ido1KO mice may be also a useful tool in the
investigations focused on the reciprocal functional
relations between Th17 and Treg cells.
Rheumatoid arthritis (RA) is an autoimmune systemic
disease affecting around 1 % of the western population
(Smolen and Aletaha 2009). In RA, activity of Th17 cells
takes over an anti-inflammatory role of Treg cells and
chronic inflammation of the joints progress (Sato et al.
2006). Collagen induced arthritis (CIA) is an animal
model of RA (Inglis et al. 2007) driven by the execrated
function of Th17 cells and abnormally low activity of
Treg (Park et al. 2011). In Ido1KO mice with CIA the
incidence of the disease has been found to be higher than
in the wild type (WT) diseased mice (Criado et al. 2009).
In addition, the severity of symptoms was higher in
Ido1KO mice with CIA than in the WT animals with CIA
(Criado et al. 2009). Thus, taken together, it was of
interest to test if deletion of Ido1 could be: (1) compen-
sated by the increased mRNA expression for Ido2 in iLN,
(2) impact mRNA expression for downstream genes on
kynurenine pathway (Afm, Kmo, Kynu, and Haao) in iLN
during CIA, (3) influence the concentration of tryptophan
and its anti inflammatory catabolites: kynurenine, AA,
and 3-HAA in iLN from Ido1KO mice with CIA, and (4)
coincide with reduced concentration of kynurenine in
serum of Ido1KO mice with CIA.
Materials and methods
Animals, CIA development and tissue harvesting
All experimental procedures were approved by the UK
Home Office. Adult C57BL/6J mice (aged 10–12 weeks)
were used in experiments (Charles River, UK). CIA was
induced as previously described (Inglis et al. 2007).
Ido1KO mice were kept and bred in the Biological
Service Unit in the Kennedy Institute of Rheumatology.
Mice were humanely sacrificed and lymph nodes were
immediately frozen and kept at -80 C.
Fig. 1 Simplified schematic representation of the kynurenine
pathway. Enzymes involved in tryptophan metabolism via the
kynurenine pathway: indoleamine 2,3 dioxygenase 1 (EC
1.13.11.17) IDO1, indoleamine 2,3 dioxygenase 2 (EC 1.13.11.52)
IDO2, arylformamidase (EC 3.5.1.9) AFM, kynurenine 3-monoox-
ygenase (EC 2.6.1.7) KMO, Kynureninase (EC 3.7.1.3), 3-hydroxy-
anthranilate 3,4 dioxygenase (EC 1.13.11.6) HAAO. Spontaneous
conversion of AA into 3-HAA has been previously reported (Ueda
et al. 1978)
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HPLC analysis and kynurenine measurements
Concentration of tryptophan, AA, and 3-HAA was
determined with HPLC method. The HPLC system
(UltiMate 3000) was provided by Dionex, UK. All
chromatographic procedures were performed in 37 C,
with C18 column (Acclaim 120, Dionex, UK) 3 lm,
120 A˚; 4.6 9 150 mm, and injection volume of 10 lL.
Tryptophan concentration was determined by HPLC
with fluorescence detection (excitation k = 284 nm;
emission k = 365 nm). The mobile phase (1 ml/min
flow rate) consisted of 50 mM acetic acid, 100 mM
zinc acetate, and 3 % acetonitrile). Concentartion of
AA and 3-HAA was determined by HPLC with
fluorescence detection (excitation k = 320 nm; emis-
sion k = 420 nm). The mobile phase (1 ml/min of flow
rate) consisted of 25 mM sodium acetate (Sigma),
1 mM acetic acid (pH5.5). Kynurenine concentration
was assessed by a colorimetric assay (Hara et al. 2008).
RNA isolation, preparation of cDNA, and qRT-
PCR
RNA was extracted using RNA-Stat60 reagent (AMS
Biotechnology) according to the manufacturer’s instruc-
tions. cDNA was transcribed using the Applied Biosys-
tems Reverse Transcription System. The total volume of
qRT-PCR reaction was 10 ll. TaqMan primer probes
were provided by Applied Biosystems UK. List of
primers is shown in the supplementary table 1. PCR
reaction was performed in a Corbett Rotor-gene 6000
thermocycler (Corbett Lifesciences, Sydney). mRNA
expression was assessed by the DDCt method.
Statistical analysis
Data was statistically analyzed using Prism 4.03
software. T test was used to compare results between
experimental groups.
Results
In a first step, the concentration of tryptophan and
kynurenine was measured in the iLN taken from naı¨ve
WT and healthy Ido1KO mice. However, it was found
that neither the concentration of tryptophan nor the
concentration of kynurenine was affected in iLN by the
deletion of Ido1, Table 1. The lack of changes in the
concentration of tryptophan and kynurenine in naı¨ve
iLN could be explained by the fact that loss of IDO1
function may be compensated by the increased expres-
sion of IDO2. Moreover, in contrast to what could be
expected, it was found that mRNA expression for Ido2
was significantly decreased (p \ 0.05) in iLN taken
from naı¨ve Ido1KO mice (Fig. 2a).
In a next step it was of interest to test if CIA could
impact the concentration of tryptophan and kynurenine
in iLN taken from WT animals with CIA and diseased
Ido1KO mice. Interestingly, the mean concentration of
tryptophan was found to be significantly (p \ 0.05)
increased in iLN taken from Ido1KO mice with CIA in
comparison with tissues harvested from WT arthritic
animals, Table 1. Moreover, the concentration of
kynurenine in iLN was not affected by CIA, Table 1.
Next, mRNA expression for Ido2 was assessed in iLN
from arthritic mice. However, mRNA expression for
Ido2 was also significantly (p \ 0.001) reduced in the
iLN taken from Ido1KO mice with CIA in comparison
with iLN taken from WT diseased mice (Fig. 2b).
It was also interesting to check if deletion of Ido1 could
impact the concentration of kynurenine in serum of
arthritic mice. However, it was found that in Ido1KO mice
with CIA the concentration of kynurenine was signifi-
cantly (p\0.001) decreased in comparison with WT
mice with CIA. In sera of arthritic WT mice the mean
concentration of kynurenine was 1.83 ± 0.24 lM. In
contrast, in sera of Ido1KO mice with CIA the mean
concentration of kynurenine dropped to 0.61 ± 0.11 lM.
In addition, it was also of interest to test if an
inactivation of IDO1 and decreased mRNA expression
for Ido2 in iLN from Ido1KO mice with CIA could be
compensated by the changes in the mRNA expression
for downstream genes (Afm, Kmo, Kynu, and Haao) on
the kynurenine pathway. However, no such effect was
observed in iLN from Ido1KO mice with arthritis in
comparison with WT mice with CIA (supplementary
figure 1). Similarly, in iLN taken from neither naı¨ve
nor from the diseased Ido1KO animals, the concen-
tration of kynurenine catabolites, AA and 3-HAA, was
significantly changed (supplementary table 2).
Discussion
The aim of this work was to investigate the impact of
Ido1 deletion on the concentration of tryptophan and
its biologically active catabolites: kynurenine, AA,
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and 3-HAA in naı¨ve iLN isolated from WT and
Ido1KO mice as well as those taken from animals with
CIA. In addition, the concentration of kynurenine was
measured in sera of Ido1KO mice with CIA and WT
arthritic animals. Metabolic data was also supported
by the results showing mRNA expression for other
genes on the kynurenine pathway in iLN upon Ido1
deletion.
Interestingly, it was found that in naı¨ve iLN taken
from Ido1KO mice the concentration of tryptophan was
not affected by the deletion of Ido1. In contrast,
tryptophan was accumulated in iLN of Ido1KO mice
upon immune challenge driven by CIA. Increased
accumulation of tryptophan in iLN from Ido1KO mice
during CIA may also emphasize a functional impor-
tance of IDO1 in the regulation of tryptophan concen-
tration in the local tissue environment (Lob and
Konigsrainer 2009; Lob et al. 2009). It is known that
upon specific conditions (e.g. acidosis) tryptophan can
be displaced from albumin (Cunningham et al. 1975).
This process may impact the metabolic flux through the
kynurenine pathway (Smith and Pogson 1980). Hence,
increased concentration of tryptophan upon deletion of
Ido1 suggests that in deed IDO1 can regulate concen-
tration of tryptophan in the local tissue environment. In
addition, in the previous papers, I have shown that the
full anti inflammatory potential of the kynurenine
pathway is likely to be achieved upon coincidence
between decreased concentration of tryptophan and
accumulation of kynurenines in iLN (Kolodziej 2012)
but not in the serum (Kolodziej 2013).
IDO2 is a relatively recently discovered enzyme
which can also mediate oxidative catabolism of
tryptophan (Metz et al. 2007). However, physiological
importance of this enzyme remains elusive. Thus,
Ido1KO mice could be a useful tool in the dissection of
IDO2 role in the regulation of tryptophan catabolism.
Moreover, here, it has been found that mRNA
expression for Ido2 was decreased in the iLN taken
from naı¨ve Ido1KO mice as well as those with CIA.
Table 1 Concentration of tryptophan and kynurenine in iLN from WT and Ido1KO mice








Tryptophan 5.11 ± 0.85 6.07 ± 3.8 5.12 ± 0.4 8.68 ± 2.4*
Kynurnine 731 ± 250.7 618.7 ± 231 998 ± 709 589.7 ± 198.1
iLN were isolated from naive and mice with CIA of C57BL/6J strain and Ido1KO mice, n = 5 for each strain and conditions. The
concentration of tryptophan was measured with HPLC method, whereas the concentration of kynurenine was measured with a
colorimetric assay. Results were assessed using t test
* p \ 0.05
Fig. 2 Decreased mRNA expression for Ido2 iLN from naı¨ve
and arthritic Ido1KO mice in comparison with WT controls.
CIA was induced in C57BL/6J mice (n = 5) and Ido1KO
animals (n = 5). Ten days after onset of the disease have been
spotted animals were sacrificed and iLN isolated. mRNA
expression for Ido2 was assessed using qRT-PCR and results
were compared with naı¨ve IDO1KO mice (n = 5) and naı¨ve
WT C57BL/6J animals (n = 5). Data was analyzed using t test.
a Significantly decreased Ido2 mRNA expression in iLN taken
from naı¨ve Ido1KO mice b significantly decreased Ido2 mRNA
expression in iLN taken from Ido1KO mice with CIA
*p \ 0.05; ***p \ 0.001
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Hence, Ido1KO mice may not be particularly suitable
for investigations of a physiological role of IDO2.
Here, it has been also found that deletion of Ido1 and
significantly reduced Ido2 mRNA expression did not
result in the abnormally changed concentration of kynu-
renine and its anti inflammatory catabolites: AA and
3-HAA in the naı¨ve iLN. Similarly, mRNA expression for
downstream genes on the kynurenine pathway: Afm, Kmo,
Kynu, and Haao were found to be not changed in iLN
taken from Ido1KO mice with CIA. However, it has to be
also acknowledged that the kynurenine pathway also
consists of metabolic branches on which biologically
active metabolites have been produced (Amori et al.
2009). It has been shown that kynurenic acid, derived from
kynurenine, influenced leucocytes (Barth et al. 2009).
Moreover, due to technical and financial limitations in this
project, it was not possible to investigate metabolic flux
through branches on the kynurenine pathway.
The concentration of kynurenine was discovered to
be significantly decreased in sera of Ido1KO mice with
CIA. This observation may be explained by two
distinct but not entirely exclusive possibilities. It may
be that upon immune challenge deletion of Ido1 is
sufficient enough to cause a decreased concentration
of kynurenine in serum but not in the iLN. Alterna-
tively, it has been shown kynurenine can be actively
transported into the T cells via the CD98 transporter
(del Amo et al. 2008). Hence, under reduced rate of
kynurenine anabolism, this process could account for
decreased concentration of kynurenine in serum
(Kolodziej et al. 2011). Moreover, this theory needs
to be experimentally tested yet.
Nonetheless, taken together, in this study it was
shown deletion of Ido1 alongside with decreased Ido2
mRNA expression resulted in the accumulation of
tryptophan in the iLN and reduced concentration of
kynurenine in sera of transgenic animals with CIA.
These results support the importance of IDO enzymes
in the regulation of tryptophan concentration in the
local tissue environment and immune system.
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